Biodesix Announces Receipt of CLIA Registration Number
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
254 Results
Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .
Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.
Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO
Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.
Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.
Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.